JP2021526834A5 - - Google Patents

Info

Publication number
JP2021526834A5
JP2021526834A5 JP2020569147A JP2020569147A JP2021526834A5 JP 2021526834 A5 JP2021526834 A5 JP 2021526834A5 JP 2020569147 A JP2020569147 A JP 2020569147A JP 2020569147 A JP2020569147 A JP 2020569147A JP 2021526834 A5 JP2021526834 A5 JP 2021526834A5
Authority
JP
Japan
Prior art keywords
sequence
sequence number
recombinant aav2
aav2 vector
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020569147A
Other languages
English (en)
Japanese (ja)
Other versions
JP7470057B2 (ja
JP2021526834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036487 external-priority patent/WO2019241206A1/en
Publication of JP2021526834A publication Critical patent/JP2021526834A/ja
Publication of JP2021526834A5 publication Critical patent/JP2021526834A5/ja
Application granted granted Critical
Publication of JP7470057B2 publication Critical patent/JP7470057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020569147A 2018-06-11 2019-06-11 組み換えaavベクター及びその使用方法 Active JP7470057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862683501P 2018-06-11 2018-06-11
US62/683,501 2018-06-11
PCT/US2019/036487 WO2019241206A1 (en) 2018-06-11 2019-06-11 Recombinant aav vectors and methods of using the same

Publications (3)

Publication Number Publication Date
JP2021526834A JP2021526834A (ja) 2021-10-11
JP2021526834A5 true JP2021526834A5 (enExample) 2022-06-15
JP7470057B2 JP7470057B2 (ja) 2024-04-17

Family

ID=67138055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569147A Active JP7470057B2 (ja) 2018-06-11 2019-06-11 組み換えaavベクター及びその使用方法

Country Status (8)

Country Link
US (1) US20210189424A1 (enExample)
EP (1) EP3802840A1 (enExample)
JP (1) JP7470057B2 (enExample)
KR (1) KR102946006B1 (enExample)
CN (1) CN112384625A (enExample)
AU (1) AU2019286386B2 (enExample)
CA (1) CA3103231A1 (enExample)
WO (1) WO2019241206A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3814492A4 (en) 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
KR20210068014A (ko) * 2018-08-20 2021-06-08 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN115710585B (zh) * 2021-08-23 2025-03-28 纽福斯(苏州)生物科技有限公司 编码nd4的核酸及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218117B1 (en) * 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
ES2541771T3 (es) * 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
WO2008101233A2 (en) * 2007-02-16 2008-08-21 University Of Florida Research Foundation Inc. Mitochondrial nucleic acid delivery systems
DE102010013829A1 (de) * 2010-03-26 2011-09-29 Carl Zeiss Microlmaging Gmbh Mikroskop und Verfahren zur Erfassung von Probenlicht
CN102634527B (zh) * 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
KR102244434B1 (ko) * 2014-08-11 2021-04-23 삼성전자주식회사 재조합 벡터 및 이를 이용한 목적 폴리펩타이드의 생산 방법
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂

Similar Documents

Publication Publication Date Title
JP7818558B2 (ja) 修飾された第ix因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用
JP7860176B2 (ja) 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
US20220331409A1 (en) Factor ix gene therapy
JP2026027271A5 (enExample)
JP2022068187A (ja) 抗体回避性ウイルスベクターのための方法および組成物
JP2020514286A5 (enExample)
JP2022065003A (ja) パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
JP2021534809A (ja) Aavカプシドの向性の再指向化
CN104520428B (zh) 将基因转移到细胞、器官和组织的aav载体组合物和方法
JP2022500066A5 (enExample)
JP2021502060A5 (enExample)
JP2020510428A5 (enExample)
JP2018537984A5 (enExample)
RU2020137429A (ru) Лечение пигментного ретинита
TW201706412A (zh) Fabry氏病基因療法
JP2022531861A5 (enExample)
JP2014507145A (ja) 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
PT1127150E (pt) ''sequências de ácido nucleico do vírus adeno associado do serotipo 1, vectores e células hospedeiras que as contêm''
AU2020231505A1 (en) Sequential intravitreal administration of AAV gene therapy to contralateral eyes
MX2023006694A (es) Tratamiento de la enfermedad de danon.
JP2018527941A5 (enExample)
JP2018509154A5 (enExample)
JP2019515663A5 (enExample)
JP2021510301A5 (enExample)
JP2024119830A5 (enExample)